Department of Oral and Maxillo-facial Implantology, Shanghai 9th People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
J Clin Periodontol. 2013 Apr;40(4):396-403. doi: 10.1111/jcpe.12066. Epub 2013 Feb 21.
To evaluate the clinical and radiographic results of dental implant placed using osteotome sinus floor elevation (OSFE) with and without simultaneous grafting.
MATERIALS & METHODS: Forty-five patients were randomly assigned into two groups: Group1: OSFE with deproteinized bovine bone mineral (DBBM) mixed with autogenous bone chips, and Group2: OSFE without grafting. The endo-sinus bone gain (ESBG) was assessed on radiographs at 6, 12, 24, 36 months following surgery as primary outcome measurement. Implant survivals and marginal bone loss (MBL) were assessed as secondary outcome measurements.
Twenty-one implants in Group1 and 20 implants in Group2 were analysed. The residual bone height (RBH) was 4.63 ± 1.31 mm in average (4.67 ± 1.18 mm for Group1 and 4.58 ± 1.47 mm for Group2). The 3-year cumulative survival rates of implants were 95.2% for Group1 and 95.0% for Group2. The ESBG in Group1 reduced from 5.66 ± 0.99 mm at 6 months to 3.17 ± 1.95 mm at 36 months, whereas the ESBG in Group2 increased from 2.06 ± 1.01 mm at 6 months to 3.07 ± 1.68 mm at 36 months. The MBL after 3 years was 1.33 ± 0.46 mm in Group1 and 1.38 ± 0.23 mm in Group2.
OSFE and simultaneous implant installation with and without grafting both resulted in predictable results. The application of grafting materials has no significant advantage in terms of clinical success.
评估使用骨凿窦底提升(OSFE)并同时进行和不进行移植的牙种植体的临床和放射学结果。
将 45 名患者随机分为两组:组 1:使用脱蛋白牛骨矿物质(DBBM)与自体骨屑混合的 OSFE,组 2:不进行移植的 OSFE。手术后 6、12、24 和 36 个月,通过放射学评估内窦骨增量(ESBG)作为主要测量结果。种植体存活率和边缘骨丧失(MBL)作为次要测量结果进行评估。
组 1 中有 21 个种植体,组 2 中有 20 个种植体。平均残留骨高度(RBH)为 4.63±1.31mm(组 1 为 4.67±1.18mm,组 2 为 4.58±1.47mm)。组 1 的种植体 3 年累积存活率为 95.2%,组 2 为 95.0%。组 1 的 ESBG 从术后 6 个月的 5.66±0.99mm 减少到 36 个月的 3.17±1.95mm,而组 2 的 ESBG 从术后 6 个月的 2.06±1.01mm 增加到 36 个月的 3.07±1.68mm。术后 3 年 MBL 在组 1 为 1.33±0.46mm,在组 2 为 1.38±0.23mm。
OSFE 和同时进行的种植体安装,无论是否使用移植材料,都能获得可预测的结果。应用移植材料在临床成功率方面没有显著优势。